Kazia Therapeutics (KZIA) Price & Analysis

Compare

304 Followers

KZIA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.86 - $39.05

Previous CloseN/A

Volume31.49K

Average Volume (3M)56.67K

Market Cap

$9.03M

Enterprise ValueN/A

Total Cash (Recent Filing)$1.66M

Total Debt (Recent Filing)$634.00K

Price to Earnings (P/E)―

Beta1.28

Next Earnings

Aug 28, 2025

EPS Estimate

>-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding1,117,859

10 Day Avg. Volume16,901

30 Day Avg. Volume56,667

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$14.00

Price Target Upside79.26% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessEncouraging early results from the Phase 1 breast cancer study show a significant reduction in circulating tumor cells for the first patient treated with paxalisib.

Financial StabilityThe breast cancer study is funded by investigators and does not require capital investments from Kazia, which is beneficial for the company's financial stability.

Market OpportunityPaxalisib is being evaluated for treating resistant triple negative breast cancer, which presents a significant market opportunity, and data from this study could be impactful.

Bears Say

Commercialization DelayThere is a delay in the potential commercialization of paxalisib for the treatment of GBM and DIPG due to delays in the clinical programs.

Financing RiskPhase 3 for glioblastoma multiforme (GBM) has not yet initiated and is financing dependent, which poses a risk for future developments.

Market ConditionsThe financing market remains difficult due to current market conditions and Kazia’s market cap.

Kazia Therapeutics News

Kazia Therapeutics announces $2M private placement

Kazia Therapeutics (KZIA) announced that it has entered into a securities purchase agreement with certain established institutional investors...

28d ago

KZIA

Kazia Therapeutics Secures $2 Million in Private Placement to Advance Oncology Programs

Kazia Therapeutics ( ($KZIA) ) has provided an announcement. On July 31, 2025, Kazia Therapeutics Limited announced a...

28d ago

KZIA

Kazia Therapeutics Announces At the Market Offering Agreement

Kazia Therapeutics ( ($KZIA) ) has shared an update. On July 25, 2025, Kazia Therapeutics Limited entered into...

1M ago

KZIA

Promising Clinical Developments and Financial Adjustments Drive Buy Rating for Kazia Therapeutics

Analyst Sean Lee CFA of H.C. Wainwright maintained a Buy rating on Kazia Therapeutics, with a price target...

2M ago

KZIA

Kazia Therapeutics target adjusted to $13 from $2 at H.C. Wainwright

H.C. Wainwright analyst Sean Lee raised the firm’s price target on Kazia Therapeutics (KZIA) to $13 from $2...

2M ago

KZIA

Kazia Therapeutics Announces Promising Early Results in Breast Cancer Trial

An announcement from Kazia Therapeutics ( ($KZIA) ) is now available. On July 9, 2025, Kazia Therapeutics announced...

2M ago

KZIA

Kazia Therapeutics reports preliminary results from Phase 1b trial

Kazia Therapeutics (KZIA) announces preliminary results from the first patient in its Phase 1b trial evaluating a combination...

2M ago

KZIA

Kazia Therapeutics trading halted, volatility trading pause

09:50 EDT Kazia Therapeutics (KZIA) trading halted, volatility trading pause Published first on TheFly – the ultimate source...

2M ago

KZIA

Kazia Therapeutics trading resumes

09:55 EDT Kazia Therapeutics (KZIA) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

2M ago

KZIA

Buy Rating for Kazia Therapeutics Driven by Promising Paxalisib Data and Strategic Developments

Kazia Therapeutics (KZIA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday....

3M ago

KZIA

Kazia Therapeutics Unveils Promising Preclinical Data for Paxalisib in Breast Cancer

Kazia Therapeutics ( ($KZIA) ) has issued an announcement. On June 11, 2025, Kazia Therapeutics announced significant preclinical...

3M ago

KZIA

Kazia Therapeutics trading resumes

10:53 EDT Kazia Therapeutics (KZIA) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

3M ago

KZIA

Kazia Therapeutics trading halted, volatility trading pause

10:48 EDT Kazia Therapeutics (KZIA) trading halted, volatility trading pause Published first on TheFly – the ultimate source...

3M ago

KZIA

Kazia Therapeutics announces publication of preclinical research on paxalisib

Kazia Therapeutics (KZIA) announced the publication of transformative preclinical research in the journal Molecular Cancer Therapeutics, a journal...

3M ago

KZIA

KZIA FAQ

What was Kazia Therapeutics Limited’s price range in the past 12 months?

Kazia Therapeutics Limited lowest stock price was $2.86 and its highest was $39.05 in the past 12 months.

What is Kazia Therapeutics Limited’s market cap?

Kazia Therapeutics Limited’s market cap is $9.03M.

When is Kazia Therapeutics Limited’s upcoming earnings report date?

Kazia Therapeutics Limited’s upcoming earnings report date is Aug 28, 2025 which is yesterday.

How were Kazia Therapeutics Limited’s earnings last quarter?

Currently, no data Available

Is Kazia Therapeutics Limited overvalued?

According to Wall Street analysts Kazia Therapeutics Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kazia Therapeutics Limited pay dividends?

Kazia Therapeutics Limited does not currently pay dividends.

What is Kazia Therapeutics Limited’s EPS estimate?

Kazia Therapeutics Limited’s EPS estimate is >-0.01.

How many shares outstanding does Kazia Therapeutics Limited have?

Kazia Therapeutics Limited has 1,117,859 shares outstanding.

What happened to Kazia Therapeutics Limited’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Kazia Therapeutics Limited?

Currently, no hedge funds are holding shares in KZIA

Company Description

Kazia Therapeutics Limited

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Kazia Therapeutics (KZIA) Earnings & Revenues

Historic Earnings Reports

KZIA Stock 12 Month Forecast

Average Price Target

$14.00

▲(79.26% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","107":"$107","212":"$212","317":"$317","422":"$422"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,107,212,317,422],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2022","6":"Jul<br/>2024","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.63,7.273846153846154,7.917692307692308,8.561538461538461,9.205384615384617,9.84923076923077,10.493076923076924,11.136923076923079,11.78076923076923,12.424615384615386,13.06846153846154,13.712307692307693,14.356153846153848,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.63,7.196923076923077,7.763846153846154,8.330769230769231,8.897692307692308,9.464615384615385,10.031538461538462,10.598461538461539,11.165384615384616,11.732307692307693,12.29923076923077,12.866153846153846,13.433076923076925,{"y":14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.63,7.12,7.609999999999999,8.1,8.59,9.08,9.57,10.059999999999999,10.55,11.04,11.530000000000001,12.02,12.51,{"y":13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":421,"date":1640995200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":344.5,"date":1643673600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":336.5,"date":1646092800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":288,"date":1654041600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96,"date":1659312000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.5,"date":1680307200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.84,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.85,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.9,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.98,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.93,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.78,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.63,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >